During the last decade the Johns Hopkins Division of Rheumatology has prioritized the development of longitudinal patient cohorts across seven disease-specific Centers of Excellence, with comprehensive clinical, diagnostic, lab, patient-reported, and imaging data, and biospecimens to facilitate discovery. These datasets have now matured to allow greater insight into how multiple factors influence the development and progression of rheumatic diseases and variation in treatment responses. Statistical methods to evaluate and interpret longitudinal data have advanced substantially in recent years, especially for identifying relevant subgroups of patients and predicting trajectories of disease progression and responses to therapy. Many of these methods were developed by members of our team and are only just beginning to be applied to medicine.
The Specific Aims of the Data Science Core are to: 1) Provide data analytical support throughout the research process that will enable investigators to generate, manage, analyze, and interpret data using modern statistical methods; 2) Develop and apply Bayesian hierarchical models (BHMs) to longitudinal cohorts bringing together with diverse sources of data to identify patient subsets predictive of different trajectories of outcomes and responses to treatments; and 3) Apply modern analytic approaches to observational and experimental studies that rigorously address heterogeneity among individuals in their responses to treatments. The Data Science Core will be led by Dr. Scott Zeger who pioneered advances in longitudinal data analysis methods, and leads the transformative Hopkins inHealth Initiative. The Data Science Core will optimize its impact and maximize productivity and efficiency by embedding biomedical data science faculty within each of our Centers of Excellence. We are confident that by working together, our clinician scientists and biomedical data scientists (biostatisticians) can accelerate the pace of research discoveries by analyzing our rich datasets carefully collected over time with new advances in statistical modeling to identify multiple factors that influence the onset and course of rheumatic diseases and better predict individual responses to different treatments that in turn can help guide evidence-based clinical practice.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR070254-02
Application #
9348591
Study Section
Special Emphasis Panel (ZAR1)
Project Start
Project End
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Wohlfahrt, Alyssa; Bingham 3rd, Clifton O; Marder, Wendy et al. (2018) Responsiveness of Patient Reported Outcomes Measurement Information System (PROMIS) Measures in RA Patients Starting or Switching a DMARD. Arthritis Care Res (Hoboken) :
Darrah, Erika; Giles, Jon T; Davis, Ryan L et al. (2018) Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis. Front Immunol 9:2696
Leung, Ying Ying; Ogdie, Alexis; Orbai, Ana-Maria et al. (2018) Classification and Outcome Measures for Psoriatic Arthritis. Front Med (Lausanne) 5:246
Bartlett, S J; Gutierrez, A K; Butanis, A et al. (2018) Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis. Qual Life Res 27:2443-2451
Darrah, Erika; Yu, Fang; Cappelli, Laura C et al. (2018) Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis. Arthritis Rheumatol :
Albayda, Jemima; Bingham 3rd, Clifton O; Shah, Ami A et al. (2018) Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events. Rheumatology (Oxford) 57:760-762
Cappelli, Laura C; Konig, Maximilian F; Gelber, Allan C et al. (2018) Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis. Arthritis Res Ther 20:59
Igusa, Takeru; Hummers, Laura K; Visvanathan, Kala et al. (2018) Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis 77:1179-1186
Cappelli, Laura C; Brahmer, Julie R; Forde, Patrick M et al. (2018) Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum 48:553-557
Lee, Yvonne C; Bingham 3rd, Clifton O; Edwards, Robert R et al. (2018) Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. Arthritis Care Res (Hoboken) 70:197-204

Showing the most recent 10 out of 22 publications